Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is based in Perth, Australia.
Часто задаваемые вопросы
В каком секторе работает Zelira Therapeutics Limited (ZLDAF)?
Zelira Therapeutics Limited относится к сектору Здравоохранение.
Какова текущая цена акций Zelira Therapeutics Limited (ZLDAF)?
По последним данным, цена акций Zelira Therapeutics Limited составляет 0,26 $, предыдущее закрытие — 0,26 $.
Выплачивает ли Zelira Therapeutics Limited (ZLDAF) дивиденды?
Нет, Zelira Therapeutics Limited не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Zelira Therapeutics Limited (ZLDAF)?
У компании Zelira Therapeutics Limited бета 0.610, что указывает на более низкую волатильность по сравнению с рынком в целом.
